First in Man Study to Evaluate Initial Safety
3
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Rnv166200 Mg
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Safety, Tolerability and Pharmacokinetics of RNV-166 in Healthy Male Volunteers
A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
Research Network
Common Treatments
- Rnv166200 Mg1
- Zp6590 Solution For Injection1
- Gl07191
Active Sponsors
- Gliknik Inc.1
- Zealand Pharma1
- InVitro Research Solutions Private Limited1
- Zealand Pharma A/S1
Top Investigators
Fortrea Clinical Research Unit Ltd.
Renovel Innovations
Profil Institut für Stoffwechselforschung GmbH
Related Conditions
- Healthy Participants Study1
- Overweight And Obese Adults1
- Weight Management1